Ganglioside GM3 is a membrane component that has been described to modulate cell growth through inhibition of EGF receptor associated tyrosine kinase. In order to determine if the inhibition of cell growth by this ganglioside is specifically mediated through EGF receptor signaling, the effects of GM3 on key enzymes implicated in EGF signaling were determined and compared to another inhibitor of the EGF receptor kinase. Treatment of A IS cells in culture by GM3 or a tyrosine kinase inhibitor, leflunomide, led to the inhibition of MAP kinase and PI3 kinase activities. There was no detectable effect on phosphotyrosine phosphatases. In a cell free system, however, GM3 had no effect on the activity of these signaling intermediates. Leflunomide was able to directly inhibit MAP kinase activity. GM3 and leflunomide were also found to act differently on the expression of the early immediate genes. The expression of c-fos and c-jun was inhibited by both GM3 and leflunomide. The expression of c-myc, however, was only inhibited by leflunomide. These findings suggest that the action of GM3 on cell growth and signaling is specifically mediated by EGF receptor and that this ganglioside does not act directly on the intracellular intermediates of EGF receptor signaling. In addition, soluble small molecule tyrosine kinase inhibitors such as leflunomide can directly affect the activity of MAP kinases and possibly other signaling intermediates. The direct effects of leflunomide on signaling intermediates may explain the differential effects of leflunomide and GM3 on gene expression and cell growth.
Introduction
Increased expression of the epidermal growth factor (EGF) receptor has been associated with several different cancers, including brain tumors (Miyaji et al, 1994) . The mechanism by which EGF exerts its mitogenic effect on the cell is an area of active investigation. Binding of EGF to its receptor results in the receptor becoming phosphorylated on tyrosine, and this allows cytoplasmic proteins containing an SH2 domain to bind directly to the phosphotyrosine sequences on the receptor. Some of these molecules include PI3 kinase, PLC-7, Grb2, and the she protein family. She and Grb2 appear to be required to bind Sos (Pelicci et al, 1992; Cherniack et al, 1995) and bring it to the plasma membrane. The interaction of Sos with the plasma membrane permits it to catalyse the exchange of GTP for GDP on p21 ras (Egan et al, 1993; Rozakis-Adcock et al. 1993) . The activated p21 ras-GTP is then able to bind and facilitate activation of Raf and other serine/threonine protein kinases, which in turn stimulate the activity of MAP kinase (Huang et al, 1993; Haystead et al, 1994) . This cascade leads to the phosphorylation of MAP kinases on both serine and threonine and thereby the activation of these enzymes (Wu et al, 1993) . The S6 kinases are one of the substrates for MAP kinases which can activate transcription factors (Bjorbaek et al, 1995; Han et al, 1995) . The genes for c-fos, c-myc, and c-jun are some of the early genes expressed in response to cell stimulation by EGF (Kalousek et al, 1994) , and the corresponding proteins may form homodimers or heterodimers that bind to DNA and lead to further gene transcription. The MAP kinase pathway described above is the most completely described EGF receptor signaling pathway from the membrane to the nucleus. Other signaling pathways implicating JNK, JAKs (Barinaga, 1995; Wright et al, 1995) , or STAT proteins (Quelle et al, 1995) have also been described to be activated by the EGF receptor.
Modulation of the mitogenic effect of EGF on the cell may be a useful therapeutic target for tumors overexpressing the EGF receptor. Several approaches have been used to target the EGF receptor system for therapy. Monoclonal antibodies (MAbs) directed against the external portion of EGF receptor have been used therapeutically (Baselga and Mendelson, 1994) . These MAbs prevent binding of ligands to the receptor, block ligand-induced activation of the receptor and can inhibit tumor cell growth. The major problems for the use of these Mabs are their immunogenicity toward the host and the difficulty of delivery into solid tumors. Tyrosine kinase inhibitors have also been used to block EGF receptor function (Yaish et al, 1988) . Typically, these are based on a family of dicyanobenzylidene or carboxybenzylidene of low molecular weight molecules that have been found to block EGF-dependent cell proliferation by inhibiting the tyrosine kinase activity of this receptor (Yaish et al, 1988; Levitzki and Gazit, 1995) . While some inhibitors have been found which are relatively specific for the EGF receptor (Yaish et al, 1988; Levitzki and Gazit, 1995) , the lack of specificity of these molecules toward the membrane and cytoplasmic kinases and their potential toxicity constitute the major difficulties in their use as anti-tumor drugs. Ganglioside GM3 has been described to play an important role in cell growth and differentiation (Hattori et al, 1995) . One way in which GM3 may exert its effects is by inhibition of the mitogenic action of EGF in cells expressing EGF receptors (Bremer et al, 1986) . The effect of this ganglioside appears to be mediated by inhibition of EGF-receptor autophosphorylation and dimerization (Bremer et al, 1986; Bremer, 1994) . If the inhibition of EGF receptor kinase by GM3 directly results in growth inhibition, the downstream steps of EGF receptor should also be inhibited. Recent data has suggested that inhibition of the EGF receptor kinase does not necessarily result in inhibition of signal transduction and EGFdependent mitogenesis (Gotoh et al, 1994) . The specificity of A.Rebbaa el al GM3 toward the EGF receptor signaling pathway will be compared to leflunomide, another protein tyrosine kinase inhibitor. This molecule is an immunosuppressive drug (Bartlett et al, 1991) that was recently found to exert its action on cells through inhibition of protein tyrosine kinases (Mattar et al, 1993) . This molecule was shown to inhibit EGF receptor autophosphorylation in A431 cells in a dose dependent manner (Mattar et al., 1993) . Its effects on IL-2 stimulated tyrosine kinase activity (p56 lck ) and other tyrosine kinases (p59 fyn and Zap70) involved in T cell activation may explain its immunosuppressive effects (Xu et al., 1995; Nikcevich et al., submitted for publication) .
Results

Effect of GM3 and leflunomide on cell growth
It was previously reported that GM3 inhibits EGF stimulated cell growth in KB and A431 cell lines (Bremer et al., 1986) . Addition of this ganglioside, but not other gangliosides, to the culture media induced a significant decrease in cell number after 5 days in culture. Leflunomide, at 50 u,M, was shown to reduce the number of human foreskin fibroblast and A431 cells by more than 70% after 4 days incubation with this drug (Mattar et al., 1993) . In this study we compared the effects of GM3 and leflunomide on the EGF-dependent growth of cultured A1S cells (derived from A431) (Hanai et al, 1988) . After 5 days in culture, the cells were counted and the results presented in Figure 1 . In the presence of EGF, the A IS cell number was double the nontreated cells . In the presence of GM3, however, EGF-stimulated cell growth was not observed. These data suggested that GM3 could only inhibit EGF-dependent cell growth. Treatment with leflunomide led to a drastic decrease in the cell number of both EGF treated and nontreated cells. Treatment with leflunomide appeared to inhibit both EGFdependent and serum-dependent cell growth.
GM3 and leflunomide inhibit EGF receptor kinase activity EGF receptor activity was assayed with a synthetic substrate (RR-src). Phosphorylation of this peptide on tyrosine residues was measured after incubating it with the receptor and [>y Fig. 1 . Effects of GM3 and leflunomide on A1S cell growth. Cells were seeded at 1 x 10* cell per well and incubated overnight in DMEM containing \0% FBS, the media was then replaced by DMEM containing 1% FBS GM3 (300 u.M) and leflunomide (50 u.M) were added to the corresponding wells and incubated for an additional 18 h. EGF(100 ng/ml) was then added to the cells and incubated for 5 days. The cells were then washed, trypsinized, and counted under a microscope. A IS cells at about 80% confluency were starved overnight in serum free media at 37°C, and then washed and lysed in lysis buffer. The activity of EGF receptor was assayed in the cell lysate by incubating 50 fig of proteins with or without GM3 (300 u.M) or leflunomide (50 |j.M) for 30 min at room temperature. EGF (100 ng/ml) was then added to the corresponding samples, and incubated in the presence of 1 mM RR-src peptide, [ P]-ATP for 10 min at room temperature. The reaction was stopped by addition of 25% TCA to each sample. The radioactivity in the nonprecipitated material was measured after filtration through phosphocellulose membranes. 1, Control without EGF; 2, control with EGF; 3, treatment with GM3 (300 JJLM) and EGF; 4, treatment with leflunomide (50 JJLM) and EGF.
EGF receptor kinase was increased about five times in the presence of EGF (lane 2). Both GM3 and leflunomide showed a significant inhibition of EGF receptor activity (lanes 3 and 4). Leflunomide appeared to be a somewhat more effective inhibitor than GM3, since it was able to return the EGF receptor kinase activity to its basal activity. In the presence of GM3, there was about a 70% reduction of the stimulated kinase activity.
Effects on EGF receptor signal transduction
Tyrosine phosphatase activity. The decrease in phosphotyrosine observed in the EGF receptor after treatment with GM3 or leflunomide could be due to either decreased kinase activity or increased tyrosine phosphatase activity. As shown in Figure 3 , the activity of the phosphotyrosine phosphatase, PTP1D, was measured in the presence or absence of these two effectors. Leflunomide (lane 3) and GM3 (lane 2) appeared to have no significant effect on the activity of this enzyme. Two wellknown inhibitors of tyrosine specific phosphatases, NaF and Na 3 VO 4 , were used as controls (lanes 4 and 5) and were able to inhibit the activity of the immunoprecipitated enzyme. These data suggest that the inhibition of EGF receptor phosphorylation by GM3 or leflunomide was not mediated by the increase of PTP1D activity in A1S cells.
P13 kinase activity. The SH2 domain of PI3 kinase interacts with phosphotyrosine residues on the intracellular domain of the EGF receptor upon its activation by EGF (Peles et al, 1992) . The activity of PI3 kinase was assayed by using the immunoprecipitated enzyme from A IS cell lysates. The substrate used for this reaction was phosphatidylinositol (PI), which in the presence of radiolabeled ATP can be phosphorylated to form radiolabeled PIP and PIP2. When the cells were preincubated with the effectors before immunoprecipitation of PI3 kinase, the activity of this enzyme was strongly inhibited by both GM3 and leflunomide ( Figure 4A ). When immunoprecipitated PI3 kinase was incubated directly with these effectors, no significant difference in the phosphorylation of PI was observed between the control and samples incubated with either GM3 or leflunomide ( Figure 4B ). These two molecules appear to affect PI3 kinase through inhibition of EGF receptor kinase activity.
Effects on MAP kinase activity. MAP kinase enzymes constitute a central crossroad in the intracellular signaling pathways since they are activated in response to several stimuli, including EGF. These enzymes may then either phosphorylate other enzymes that activate transcription factors or enter the nucleus and directly activate transcription factors (Seth et al, 1992) . The effects of GM3 and leflunomide on MAP kinase activities are shown in Figure 5 . The activity of this enzyme was quantitated by measuring the phosphorylation of an artificial substrate, myelin basic protein (MBP). The level of MAP kinase activation after EGF stimulation is shown in lane 2 of Figure  5A . The phosphorylation of MBP observed in this lane corresponds to the activity found in cells preincubated with EGF before lysis and immunoprecipitation of MAP kinase (erkl). As seen in Figure 5A , both GM3 and leflunomide were able to inhibit MAP kinase activity in intact cells. The ability of GM3 to inhibit MAP kinase activation was quantitated to determine if the inhibition was significant. The results shown in Figure  5C showed significant inhibition of MAP kinase activation in the presence of 200 (JLM GM3. Student's Mest comparison of the EGF stimulated bar with the GM3 added showed a significant difference at the 0.05 level. Addition of 300 (xM GM3 showed even greater inhibition ( Figure 5A ). Interestingly, incubation with GM3 or leflunomide directly with the activated and immunoprecipitated MAP kinases showed a different profile ( Figure 5B ). GM3 had no effect on the phosphorylation of MBP even at 300 (iM, and leflunomide exhibited a strong inhibitory effect on the activity of MAP kinase. The MAP kinases are serine/threonine kinases. Previously, leflunomide had only been shown to inhibit tyrosine kinase activity (Mattar et al, 1993) , but these data indicate that leflunomide can have a direct effect on a serine/theonine kinase. GM3 seems to exert its effect on cell signaling only through EGF receptor tyrosine kinase.
Modulation of the early immediate gene expression by GM3 and leflunomide
The kinetics of expression of mRNAs corresponding to c-fos, c-myc, and c-jun were measured upon stimulation of A IS cells with EGF that had been pretreated with GM3 or leflunomide for 24 h. Detection of mRNA was performed by specific radiolabeled probes and quantitated with a phosphoimage analyzer as described in Materials and Methods. The time course of expression for c-fos, c-jun, and c-myc in the presence or absence of GM3 or leflunomide is shown in Figure 6 . The expression of all these genes was stimulated when the cells were incubated with EGF. Both GM3 and leflunomide were able to inhibit the expression of c-fos and c-jun by about 50-60% after 60 min of EGF stimulation, which was the time of peak c-fos and c-jun expression in the control cells. The expression of c-myc, however, was inhibited only by leflunomide. These data suggest that GM3 and leflunomide may lead to inhibition of cell growth by acting upon different signal transduction pathways.
Discussion
Glycosphingolipids, and particularly gangliosides, have been implicated in many biological functions of the cell. Their location on the outer leaflet of the lipid bilayer of the plasma membrane make them specific mediators for cell adhesion (Mugnai et ai, 1994) . Changes in the structure, synthesis, and cell surface exposure of glycosphingolipids were found to be associated with metastatic phenotype in various experimental tumor systems (Liepkalns et ai, 1990; Zebda et al., 1995) . Ganglioside GM3, in addition to its participation in many extracellular events (Zheng et al., 1993; Mugnai et al., 1994) , has also been found to modulate cell growth, presumably by inhibition of EGF receptor phosphorylation (Bremer et al., 1986) . Gangliosides have been shown to modulate the receptor phosphorylation of growth factor receptors in addition to the EGF receptor. Platelet-derived growth factor receptor autophosphorylation can be inhibited by GM1 (Bremer et al., 1984) and by other ganglio-series gangliosides (Yates et al., 1993) . The insulin receptor autophosphorylation can be inhibited by sialosylparagloboside (Nojiri et al, 1991) . More recently GM1 has been found to enhance nerve growth factor stimulated phosphorylation by direct interaction with the Trk receptor (Mutoh et al, 1995) . These data have all suggested that gangliosides can affect cell growth by modulation of growth factor receptors. The goal of this study was to determine if GM3 could directly affect cell growth by inhibition of the EGF receptor kinase. In order to accomplish this, the effects of EGF receptor kinase inhibition on signaling intermediates were examined. The effects of GM3 were compared to those of leflunomide, another tyrosine kinase inhibitor.
As shown in Figure . After centrifugation, a chloroform:methanol (1:1) mixture was added to the supernatant. After vortexing and centnfugation, the lower phase containing phosphatidylinositol derivatives (PIP, PIP2) was resolved by thin layer chromatography (TLC). The radiolabeled material was detected on TLC by autoradiography. B, the enzyme was immunoprecipitated from AIS cells treated only with EGF. The rmmunocomplex was then incubated with GM3 or leflunomide at the indicated concentrations for 30 min at room temperature. The enzyme activity was then assayed as described for A.
cell growth in the absence of EGF, but EGF-stimulated cell growth was blocked. Leflunomide, on the other hand, inhibited the growth of AIS cells both in the presence and absence of EGF. These data indicate that leflunomide can affect serumdependent cell growth in addition to EGF-dependent cell growth. Leflunomide is able to inhibit PDGF-dependent growth (Mattar et al, 1993) . PDGF is one of the mitogens found in serum (Heldin etal, 1985) . The ability of leflunomide to inhibit PDGF or other growth factor induced mitogenesis may explain the ability of lefunomide to inhibit serum induced growth. GM3 has no effect on PDGF induced cell growth or tyrosine phosphorylation (Bremer et al, 1984) . The concentrations of GM3 (>150 u,M) used to inhibit cell growth and tyrosine phosphorylation are consistent with the concentrations previously reported to inhibit EGF-dependent cell growth (Bremer et al., 1986; Hanai et al., 1988) . The concentration of added ganglioside is high compared to the amount of GM3 found on AIS cells (Hanai et al., 1988) , suggesting that GM3 may be a pharmacological modulator rather than a physiological modulator of the EGF receptor. Considering that GM3 in solution exists predominantly in aggregate structures (Sonnino et al., 1994) and that only a very small quantity of the added ganglioside is incorporated into the cell (Bremer et al, 1984) , the effective concentration of added ganglioside is probably very small and on the same order of magnitude as the amount of ganglioside found in AIS cells. When the small amount of added ganglioside that is actually inserted into the cell membrane is considered, the possibility that physiological changes in the amount of cell surface GM3 could effect EGF-dependent cell growth remains. Alterations in the physiological levels of GM3 have been shown to affect EGF-dependent cell growth and phosphorylation. Decreased endogenous GM3 expression has been associated with increased EGF receptor autophosphorylation and EGF-dependent proliferation (Weis and Davis, 1990) . GM3, therefore, may be a naturally occurring modulator of the EGF receptor and much more specific than a tyrosine kinase inhibitor such as leflunomide.
GM3 and leflunomide have both been shown to inhibit EGF receptor phosphorylation (Bremer et al, 1986; Mattar et al, 1993) . The previous in vitro studies had indicated a direct effect on the kinase activity. In an intact cell system, increased phosphotyrosine specific phosphatase activity could also reduce phosphotyrosine on the EGF receptor and diminish kinase activity. The contribution of phosphotyrosine phosphatase activity was examined on both GM3 and leflunominde inhibition of EGF receptor phosphorylation. The effects of GM3 and leflunomide on phosphatases were tested in both the total cell lysate and on immunoprecipitated PTP1D. As shown in Figure  3 , neither GM3 nor leflunomide had a significant effect on the activity of this enzyme, suggesting that these effectors act directly on EGF receptor kinase and that increased phosphotyrosine specific phosphatase activity does not contribute to the decreased phosphorylation and kinase activity.
Autophosphorylated tyrosine residues on the EGF receptor bind to SH2-domain containing signaling molecules and these are then often themselves phosphorylated by the receptor kinase (Boonstra et al, 1995) , thus initiating the signaling cascades. PI3 kinase is one of the SH2-domain containing en- when EGF receptor kinase activity was inhibited. In preliminary experiments, GM3 and leflunomide seemed to be able to inhibit S6 kinase activity in intact cells but could not inhibit purified S6 kinase activity (data not shown). These results were similar to the PI3 kinase inhibition results presented here (Figure 4) . These data indicate that inhibition of the EGF receptor kinase by GM3 can block SH2-domain dependent signaling. The MAP kinase signaling pathway is a well defined signaling pathway activated by EGF (Cobb and Goldsmith, 1995) . Activation of the MAP kinase pathway by the EGF receptor can be accomplished by two different sets of adaptor proteins (SHC or Grb2/Sos) that result in the activation of p2l ras and the MAP kinase cascade (Sasaoka et al, 1994) . Both SHC and Grb2/Sos adaptor proteins contain SH2 domains that allow them to bind to activated EGF receptors. Recently, however, it has been found that EGF receptors unable to bind SH2-domain proteins are still able to activate the MAP kinase pathway (Campos-Gonzalez and Glenney, 1992; Gotoh et al., 1994) . These data have suggested that the EGF receptor may use auxiliary or non-tyrosine kinase dependent signals that result in the activation of pathways crucial for mitogenesis. In order to determine if GM3 could inhibit these auxiliary signals as well, zymes that binds to the tyrosine phosphorylated EGF receptor and is activated by EGF (Peles et al., 1992) . As shown in Figure 4A , both GM3 and leflunomide strongly inhibit the activity of PI3 kinase when the cells were incubated with those effectors before immunoprecipitation of PI3 kinase. When either GM3 or leflunomide were incubated with purified PI3 kinase, there was no effect on the activity ( Figure 4B ). These data indicate that there is no direct effect of GM3 or leflunomide on PI3 kinase activity. This activity was modulated only 
c-myc
Time After EGF Stimulation (min.) Fig. 6 . Expression of c-myc, c-jun, and c-fos. The cells were treated with or without GM3 or leflunomide for 24 h, and EGF was added to the corresponding flasks for the indicated times. Total RNA was then extracted, electrophoresed, and transferred to Duralon nylon membrane, c-fos, c-jun, and c-myc were detected on the membrane with specific radiolabeled probes. The corresponding bands were visualized and quantitated by a phosphoimage analyzer. Data was normalized to the expression of B-actin.
the ability of GM3 to inhibit MAP kinase activity was determined. MAP kinase activity was determined using myelin basic protein as a substrate. When the cells were preincubated with these effectors prior to immunoprecipitation and kinase assay, both GM3 and leflunomide were able to inhibit the activity of this enzyme ( Figure 5A ). This inhibition suggested that GM3 may be able to inhibit EGF-dependent signals in addition to inhibition of the EGF receptor kinase. GM3 appears to prevent activation of the EGF receptor by inhibition of receptor dimerization (Bremer, 1994) , suggesting that all EGF receptor dependent signaling should be inhibited. When GM3 and leflunomide were incubated directly with immunoprecipitated MAP kinases, GM3 had no effect on the activity but leflunomide had a strong inhibitory effect ( Figure 5B ). These data suggested that leflunomide directly inhibits MAP kinase. The action of GM3, on the other hand, is indirect and presumably by its inhibition of the EGF receptor. The EGF receptor signal transduction pathways lead to the stimulation of early-immediate genes in the nucleus. These genes code for transcription factors which in turn stimulate the expression of other genes. The ability of either GM3 or leflunomide to affect this end product of signaling pathways was also investigated. Leflunomide inhibited the EGF stimulated expression of c-fos, c-jun, and c-myc in A1S cells. GM3, however, was only able to inhibit c-fos and c-jun expression (Figure 6) . The inhibition of c-fos and c-jun by GM3 is consistent with the inhibition of MAP kinase activity by GM3. Kinasedeficient EGF receptors have been shown to stimulate c-fos expression as well as MAP kinase (Eldredge et al., 1994) . These data again suggest that GM3 can inhibit non-tyrosine kinase signaling by the EGF receptor. The inability of GM3 to inhibit c-myc expression was surprising since GM3 appeared to be an effective inhibitor of EGF mediated signaling. On the other hand, c-myc expression is highly influenced by the serum response element (SRE) (Whitmarsh et aL, 1995) and serum factors may be able to overcome the inhibition of EGF signaling by GM3. Since leflunomide is inhibiting serum-dependent proliferation, it is probably also affecting SRE activation. The inhibition of MAP kinase activation by GM3 is not complete ( Figure 5C ), and therefore the MAP kinase activity that is present may be sufficient to stimulate the expression of c-myc.
In conclusion, this study demonstrates how GM3 can inhibit cell growth by inhibition of the EGF receptor kinase. The ability of GM3 to inhibit the EGF receptor kinase has been shown to be dependent on the carbohydrate moiety. Other gangliosides have no effect on kinase activity or EGF-dependent cell growth (Bremer et al., 1986) and chemical modification of the GM3 oligosaccharide alters the inhibitory activity (Bremer, 1994) . Furthermore, NANALac coupled to BSA is able to inhibit EGF receptor kinase activity and cell growth similar to GM3 (Bremer et al., 1995) . The data presented here suggest that GM3 is also a fairly specific inhibitor of EGF mediated signal transduction. As expected, signal transduction that is dependent on the kinase activity was inhibited (PI3 kinase). In addition, GM3 appeared to also partially inhibit MAP kinase activity which can be stimulated by kinase defective EGF receptor mutants (Campos-Gonzalez and Glenney, 1992) . Leflunomide, chosen as a model tyrosine kinase inhibitor, appeared to have different effects on cell growth and certain signaling steps. These differences can probably be accounted for by the ability of leflunomide to directly inhibit signaling intermediates (MAP kinase) and other growth factor receptors (PDGF, IL-2) (Mattar et al., 1993) . The difference of action of these two effectors on the cytoplasmic intermediates of EGF receptor signaling may also explain the difference in their effects on early gene expression.
Thus, GM3 may constitute an additional tool for targeting the EGF receptor in tumors that overexpress this receptor. The use of this ganglioside as a therapeutic agent to target the EGF receptor will depend on its efficiency and its specificity toward this receptor. Previous data had suggested the specificity of GM3 for the EGF receptor (Bremer, 1994) . The data presented here suggests that the effects of GM3 on signal transduction may be limited to EGF stimulated events. Therefore, GM3 or GM3-like molecules may be an interesting tool to study EGF receptor signal transduction and a possible therapeutic tool.
Materials and methods
Materials A1S cells were a gift from Dr. Carol McCleod, UCSD. They were cloned from the A431 human epidermoid cell line and selected to be responsive to EGF (Hanai et al., 1988) . DMEM media and fetal bovine serum (FBS) were purchased from BioWhittaker (Walkersville, MD). Leflunomide A77 1726 was supplied by Hoechst, AG, Weisbaden, Germany. GM3 was extracted from dog blood following a standard procedure (Momoi et al., 1976) and purified by HPLC, and its punty was verified by TLC. EGF, protein A-agarose, myelin basic protein (MBP), paranitrophenylphosphate (pNPP), and RR-src were purchased from Sigma (St. Louis, MO). [Y^PJ-ATP (9.25 MBq) was from Dupont NEN (Boston, MA). Antibodies against MAP kinases, PI3 kinases, and PTP1D were purchased from UBI (Lake Placid, NY).
Determination of cell growth
A1S cells were cultured in DMEM media containing 10% FBS and supplemented with penicillin (50 units/ml), streptomycin (50 u.g/ml), and Lglutamine (2 mM) and incubated at 37°C in a humidified 95% air, 5% CO 2 incubator for various times as indicated below. To measure cell growth, 1 x 10 4 cells/ml were seeded in 24 well plates in DMEM containing 10% FBS, and incubated overnight at 37°C. The medium was then replaced by DMEM/1% FBS and the cells incubated for an additional day in the presence of GM3 (150 u.M) or leflunomide (50 u.M). EGF (100 ng/ml) was then added to the wells and the cells incubated for an additional 5 days. The cells were then washed with PBS, treated with trypsin, and counted under a microscope with a hemocytometer
EGF receptor kinase activity
Cells were seeded 3 days prior to kinase assay in 25 cm 2 flasks containing DMEM media supplemented with 10% FBS. When the flasks were 80% confluent, they were transferred to serum free media and incubated overnight at 37°C. After washing with cold PBS, the monolayer was solubilized by the addition of 200 u.1 lysis buffer containing 50 mM HEPES (pH 7.4), 150 mM NaCl, 100 mM NaF, 1 mM MgCl 2 , 1.5 mM EGTA, 200 u.M sodium orthovanadate, and 1% NP-40. Phosphorylation of a synthetic peptide, RR-src, by the EGF receptor associated tyrosine kinase was accomplished (Northwood and Davis, 1998) by incubating 50 u,g of protein from the cell lysates both with and without effectors in a 40 u.1 final volume of phosphorylation buffer (50 mM HEPES pH 7.4, 5 mM MgCI 2 , 5 mM MnCl 2 , 200 u.M Na 3 VO 5 , 1 mM NaF, 0.1 mM PMSF, 10 u.g/ml leupeptin). After 30 min at room temperature, 100 ng of EGF was added to the samples followed by 1 mM synthetic peptide RR-src, 10 u.M ATP, and 10 u.Ci [y^Pl-ATP. The reaction was stopped after 10 min at room temperature by the addition of 20 u.1 of 25% TCA. The precipitated proteins were eliminated by centrifugation, and the supernatant containing the peptide RR-src was applied to a phosphocellulose membrane placed in Eppendorf tubes (SpinZyme Basic Separation Unit from Pierce, Rockford, IL) in order to eliminate the unincorporated radiolabeled ATP After washing, the membrane was transferred to a scintillation vial for counting of the associated radioactivity.
Phosphatase assay
Phosphatase activity was measured as described previously (Mansbndge et al., 1992) and outlined briefly below. Cell lysates from confluent 25 cm 2 flasks were incubated overnight at 4°C with anti-PTPID antibody completed to protein A-agarose. The immunocomplex was then washed three times with PBS and once with phosphatase buffer (20 mM HEPES (pH 7.0), 60 mM NaCl, 60 mM KC1, 0.1 mM PMSF, 1 u.M pepstatin, 1 u.g/ml aprotinin, 1 jig/ml leupeptin). The pellet was resuspended in 60 u.1, and the effectors added in 20 |xl of phosphatase buffer. After 30 min incubation at room temperature, 20 (ig of pNPP dissolved in phosphatase buffer was added to the reaction mixture and incubated for 20 min at 30°C. Samples were then centrifuged for 10 s at 12,000 x g, and 0.9 ml of IN NaOH were added to the supernatant. Phosphatase activity was quantitated by measuring the optical density at 410 nm.
PI3 hnase activity
A1S cells were incubated with and without effectors overnight as described above, and then 100 ng/ml EGF was added to the flasks. PI3 kinase assay was performed as previously described (Kim et al., 1994) . Cell lysates (500 \xj> to 1 mg protein) were incubated overnight at 4°C with 2 u.g of anti-PI3 kinase complexed to protein A-agarose. The immunoprecipitates were then washed three times with PBS and one time with TNE buffer (10 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA). For experiments with the purified enzyme, the immunoprecipitates from cells treated only with EGF were incubated both with and without effectors for 30 min at room temperature before the enzyme assay. The beads were then resuspended in a solution containing 50 (il of TNE, 20 u.g of phosphatidylinositol, 10 u.1 of 100 mM MgCl 2 , and 5 |xl of radiolabeled ATP solution (10 u.Ci [-/"PJ-ATP, 10 u.M ATP in TNE buffer). After a 20 min incubation at 30°C, the samples were centrifuged for 10 s at 12,000 x g. To the supernatant, 20 u.1 of HCL (6N) and 160 u.1 of chloroform-methanol (1:1) were added. This mixture was then vortexed briefly and the phases separated by centnfugation. The chloroform phase was then spotted on a thin layer chromatography plate and resolved by a mixture of 60:40 (v/v) propanol0.5N acetic acid.
MAP kinase activity
Phosphorylation of MBP by MAP kinase was performed as previously described (Seger et al., 1994) . In this study, MAP kinase activity was measured from cells when cells were preincubated with effectors and with effectors added directly to the kinase reaction mixture.
When cells were preincubated with effectors as described above, 100 ng/ml of EGF was added to each flask and incubated for 10 min prior to harvest. After washing with cold PBS, the cells were lysed and the lysates centrifuged at 12,000 x g for 10 min to eliminate paniculate material. The cell lysates were then incubated overnight with 5 u.g of anti-Rat MAP kinase R2 (anti-erkl) antibody linked to protein A-agarose at 4°C. Immune complexes were washed three times with PBS and then once with phosphorylation buffer (same as EGF receptor kinase buffer). When GM3 or leflunomide were added directly to the reaction mixture they were incubated for 30 min at room temperature with the immunoprecipitated enzyme before determination of activity.
Phosphorylation of MBP was measured directly on the beads containing immunoprecipitated MAP kinase by addition of 0.25 mg/ml MBP in a total volume of 50 |il assay buffer (20 mM MOPS pH 7.2, 25 mM B-glycerol phosphate, 5 mM EGTA, 1 mM sodium vanadate, 1 mM dithiothreitol), followed by 10 (J.M ATP containing 10 u.Ci of [7 32 P]-ATP to each sample. After 10 min incubation at 30°C, the reaction was stopped by the addition of 12 JJLI of Laemmh buffer and then boiled for 2 min. The samples were then analysed by SDS-PAGE on a 12% acrylamide gel, followed by autoradiography of the dried gel.
Expression ofc-fos, c-myc, and c-jun
For Northern blot analysis of c-fos, c-jun, and c-myc expression, total RNA was isolated from 5 x 10 7 to 1 x 10* cells using the guanidinium acid/ isothiocyanate method (Chomczynski et al., 1987) followed by CsCl 2 centnfugation. Total RNA (30 u.g per lane) was electrophoresed in a formaldehyde denaturation gel containing ethidium bromide and transferred to a Duralon nylon membrane (Stratagene, La Jolla, CA). After UV cross-linking, blots were hybridized with [ 32 P]-radiolabeled cDNA probes synthesized from c-fos, c-jun, or c-myc containing plasmids (American Type Culture Collection) using a random priming kit (Boehringer-Mannheim Biochemicals, Indianapolis, IN) and QuikHyb solution (Stratagene, La Jolla, CA) and then washed at 60°C. The blots were then analysed and the bands were quantitated with a GS-250 Molecular Imager Analyzer (Bio-Rad, Hercules, CA).
